Latest Regulatory News

Carbonxt Group has successfully closed its non-renounceable pro-rata entitlement offer, issuing over 51 million Loyalty Options and raising approximately $514,000 to support its expansion plans.

Cleo Diagnostics has received encouraging feedback from the U.S. FDA on its ovarian cancer pre-surgical triage test, reinforcing its clinical trial design and regulatory strategy ahead of a critical 510(k) submission.

TMK Energy Limited’s securities have been suspended from ASX trading due to a missed periodic report deadline, raising questions about the company’s regulatory adherence and market outlook.

Black Rock Mining Limited has announced a $12 million capital raising via a two-tranche placement and a Share Purchase Plan (SPP) to fund early works at its Mahenge Graphite Project. The offer includes new shares priced at $0.021 each with free options exercisable at $0.03, subject to shareholder approval and ASX quotation.

AMP has reached an agreement in principle to settle a long-running class action over fees and interest rates on certain superannuation funds, agreeing to pay $120 million subject to court approval.

Forrestania Resources is set to begin a two-phase drilling program at its Hyden Project following regulatory approval and the settlement of legal disputes over tenements.

Zeotech Limited has locked in a binding five-year offtake agreement with MSI, granting exclusive marketing rights for its kaolin products across key Asian markets. This deal, valued at approximately AUD 204 million, sets the stage for early cash flow generation and advancement of its low-carbon concrete additive project.

Bioxyne Limited has secured import permits and purchase orders worth A$5.1 million for medical cannabis in Germany, signaling strong early traction in a key European market.

Yari Minerals has raised $1.5 million through a share placement to fund its first drilling campaign at the South Rolleston Coal Project, aiming to upgrade its coal resource classification and confirm metallurgical quality.

Actinogen Medical has reached a pivotal agreement with the US FDA outlining the regulatory and clinical trial requirements for Xanamem’s approval in Alzheimer’s disease, setting a clear path toward a US marketing application.

Washington H. Soul Pattinson and Brickworks have secured Supreme Court approval for their share schemes, paving the way for the launch of Topco shares on the ASX. Shareholders will transition to Topco shares starting next week, marking a significant step in the companies’ strategic consolidation.

AVITA Medical has secured the CE Mark for its innovative RECELL GO device, paving the way for commercialization across key European markets including Germany, Italy, and the UK. This regulatory milestone expands the company’s footprint in acute wound care.